The leading MIDD consultancy in the world
We are the leading and largest model-informed drug development (MIDD) consultancy in the world, which enables us to assure that various career pathways are offered to match the ambition and personal interests of our employees.
The Integrated Drug Development Team at Certara delivers value by applying MIDD concepts and solutions into the most crucial drug development deliverables – to inform internal decision-making and strengthen global regulatory submissions. Leveraging our experience in working on thousands of drug development projects on behalf of hundreds of biopharma companies, we bring a track record of success and a broad range of expertise to each assignment.
Be a part of Certara’s growing global team of leading experts and make a difference in the world.
- Collaborate with leading drug development experts
- Work on a wide range of innovative drug development programs
- Enjoy flexibility, competitive benefits and a culture of passion and fun
Director, Pharmacometrics
Pharmacometricians are responsible for supporting quantitative decision-making in drug development through the development and application of population PK, PK/PD, exposure-response and other models. Pharmacometricians will have the ability to work on a variety of therapeutic indications and data types and must be experts in applied Population PK, PK/PD, and/or exposure-response modelling and simulation to support drug development.
Senior Director, Pharmacometrics
We are looking for a regional leader to lead and expand a number of well-functioning consulting teams across Europe. In this role, you will be driving the career development of existing staff as well as the recruitment of new talent. Together with the broader IDD team, you will be supporting and leading strategic early and late clinical development engagements with our clients by providing fit for purpose pharmacometrics solutions that address key questions in their development programs, clinical study design considerations, model-informed drug development strategies, as well as interactions with and submissions to regulatory authorities.
Associate Director, Pharmacometrics
Our Pharmacometricians are responsible for supporting quantitative decision-making in drug development through the development and application of population PK, PK/PD, exposure-response and other models. Qualified candidates will have the ability to work on a variety of therapeutic indications and data types and must be experts in applied Population PK, PK/PD, and/or exposure-response modelling and simulation to support drug development.
We are looking for Pharmacometricians that want to:
- Deepen their strategic drug development expertise and their experience informing drug development decisions.
- Hone their pharmacometric techniques with fit-for-purpose modelling approaches leveraging e.g. model-based meta-analysis, target-mediated drug disposition models, and E-R trial-simulations.
- Broaden their drug development expertise by working with a myriad of companies, molecular modalities, and therapeutic areas.
- Develop their consulting career path by recognizing and seeking opportunities that match their ambition and personal interests.
Dr. Taylor joined Certara in March 2011. She holds a PhD in Chemical Engineering from Pennsylvania State University. At Certara, Dr. Taylor leads consultancy projects, performing population PK, PK/PD, efficacy and safety exposure-response, and concentration-QTc modeling to support regulatory filings, study design and general drug development.
サターラでは、Matthew Zierhut博士が、モデルに基づくメタ解析（model-based meta-analysis：MBMA）により、 外部の集積された臨床試験データを開発の意思決定および商品化・規制戦略に統合することを推進しています。Mattは臨床開発チームと密接に連携し、最も重要な意思決定を行う際にMBMAが最適な効果を発揮するよう、活用しています。
Dr. Taylor joined Certara in March 2011. She holds a PhD in Chemical Engineering from Pennsylvania State University. At Certara, Dr. Taylor leads consultancy projects, performing population PK, PK/PD, efficacy and safety exposure-response, and concentration-QTc modeling to support regulatory filings, study design and general drug development.
サターラでは、Matthew Zierhut博士が、モデルに基づくメタ解析（model-based meta-analysis：MBMA）により、 外部の集積された臨床試験データを開発の意思決定および商品化・規制戦略に統合することを推進しています。Mattは臨床開発チームと密接に連携し、最も重要な意思決定を行う際にMBMAが最適な効果を発揮するよう、活用しています。
